Roswell Park Cancer Institute (RPCI) is requesting support to continue its participation in the Cancer and Leukemia Group B (CALGB). The goals of our participation in CALGB include the following: (1) to continue our strong contribution to the scientific agenda of the Group, (2) to continue our performance of pilot activity at the local level that can be considered for Group adaptation, (3) to continue our administrative support for the efficient functioning of the Group, (4) to sustain accrual in order to allow the rapid accumulation of clinical data and experience through the cooperative group process, and (5) to continue to provide data of high quality in a timely manner. Over the last grant period, we have contributed substantially to the scientific, administrative, core, and publication activities of the CALGB. More specifically, 6 RPCI members serve or have served as chairs or vice chairs of scientific committees;16 serve or have served as members on scientific committees;12 serve or have served as study chairs or vice-chairs on 22 protocols;3 have protocols under consideration;9 provide or have provided core services to the Group;and 5 have performed pilot studies that have led to the development of CALGB protocols. RPCI members have contributed to 71 publications and given 58 education sessions. Furthermore, 8 members have or have had administrative roles in the Group. RPCI also represents an ongoing resource of ideas for future CALGB science;RPCI has a vigorous Phase I/I I program with many protocols potentially exportable to the Group. CALGB accrual by RPCI is customarily between 200-250 credits/year. Data quality and timeliness of submission has met Group standards. The campus spans 25 acres in downtown Buffalo and consists of 10 research and clinical buildings with approximately one million square feet of space. Statistics for fiscal year 2006-2007 include 6805 new cancer cases, 4215 hospital admissions, and 161,869 outpatient visits from patients in 36 states and 5 foreign countries. Both the inpatient and the outpatient centers are located in a spacious facility that opened in 1998.
The aim of inter-Institutional cooperative clinical research, as exemplified by the CALGB, is to advance our understanding of malignant diseases and, thereby, improve our ability to treat people afflicted with them. Cooperative group research answers important therapeutic questions through large clinical trials and allows integration of information obtained from basic science and from economic and psychosocial investigations.
|DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306|
|Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91|
|Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7|
|Nwogu, Chukwumere E; D'Cunha, Jonathan; Pang, Herbert et al. (2015) VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance). Ann Thorac Surg 99:399-405|
|Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9|
|Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7|
|Wetzler, Meir; Watson, Dorothy; Stock, Wendy et al. (2014) Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 99:111-5|
|Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10Â 002. Br J Haematol 165:102-11|
|Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38|
|Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50|
Showing the most recent 10 out of 49 publications